Hormonal signaling in the gut

Clémence D. Côté¹² *, Melika Zadeh-Tahmasebi¹² *, Brittany A. Rasmussen¹², Frank A. Duca¹³ & Tony K.T. Lam¹²,³⁴

* Authors contributed equally to this review.

¹Toronto General Research Institute, University Health Network, Toronto, ON, Canada, M5G 1L7, Departments of Physiology and Medicine, University of Toronto, Toronto, ON, Canada, M5S 1A8, ⁴Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada, M5G 2C4

The gut is anatomically positioned to play a critical role in the regulation of metabolic homeostasis, providing negative feedback via nutrient sensing and local hormonal signaling. Gut hormones, such as CCK and GLP-1, are released following a meal and act on local receptors to regulate glycemia via a neuronal gut-brain axis. Additionally, jejunal nutrient sensing and leptin action are demonstrated to suppress glucose production and both are required for the rapid anti-diabetic effect of duodenal jejunal bypass surgery. Strategies aimed at targeting local gut hormonal signaling pathways may prove to be efficacious therapeutic options to improve glucose control in diabetes.

Introduction

Diabetes is now a worldwide epidemic affecting approximately 350 million people worldwide (1). Almost 80% of type 2 diabetic individuals are overweight or obese (2) due in part to the interaction between genetics and the environment, such as overconsumption of a hypercaloric, western diet that is associated with a dysregulation in glucose homeostasis (3). As hyperglycemia is a primary cause of diabetic complications and accounts for the majority of economic costs associated with diabetes (4), current therapeutic approaches to treat diabetes and to lower the associated economic burden are focused on regulating glucose levels and hepatic glucose production (GP). Indeed, metformin is the most widely prescribed diabetic drug, normalizing glycemia through a reduction in GP (5). However, metformin has side effects, leading to the development of the recent oral hypoglycemic agents aimed at increasing circulating levels and action of gut-derived incretins, such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide 1 receptor (GLP-1R) agonists (exenatide and liraglutide). The early success of these treatments highlights the importance of the gastrointestinal tract in regulating glucose homeostasis.

Indeed, the gastrointestinal tract is anatomically positioned as the first line of defense to prevent nutrient excess by initiating negative feedback mechanisms through nutrient-induced secretion of gastrointestinal hormones (Figure 1). Starting in the stomach, ghrelin is an orexigenic peptide, with increased ghrelin levels associated with the timing of a meal (6, 7), while intake of nutrients suppresses ghrelin levels associated with the timing of a meal (6, 7), while intake of nutrients suppresses ghrelin secretion in both rodents and humans (8, 9). Although ghrelin may act in an endocrine fashion (10, 11), vagal afferents innervating the stomach express the ghrelin receptor and in both rodents and humans, a vagotomy (which disrupts communication between the stomach and brain), abolishes the ability of ghrelin to increase food intake (12, 13), suggesting a local (paracrine) effect. In addition to its effects on food intake, ghrelin regulates glucose homeostasis by increasing the gastric emptying rate (14) and inhibiting glucose stimulated insulin secretion (15). More distally to
the site of ghrelin secretion, the small intestine contains a variety of regulatory signals (Figure 1) including: i) the more proximal hormones within the duodenum and jejunum, cholecystokinin (CCK) in I cells and glucose-dependent insulino tropic polypeptide (GIP) in K cells, and ii) more distal hormones in the ileum and large intestine within L cells, glucagon-like peptide-1/2 (GLP-1/2), oxyntomodulin (OXN), and peptide YY (PYY). The secretion of these hormones are stimulated by nutrients within the intestine that then act on their respective receptors either centrally, or locally on vagal afferents that are in close proximity to enteroendocrine cells (EECs), to regulate metabolic homeostasis through various changes in food intake, gastric emptying, intestinal motility, and or energy expenditure (see (16)). In light of this evidence, we put forward a working hypothesis that nutrient-induced gut-derived hormones activate local gut signaling events to trigger the central nervous system via the vagus nerve to regulate glucose homeostasis.

**CCK Action in the Duodenum**

CCK is secreted from EEC I-cells predominantly located in the proximal small intestine, mainly in response to fatty acids (Figure 1) (17). Besides promoting satiation through a neuronal network, endogenous CCK also mediates the ability of intestinal lipids to lower GP via a gut-brain-liver neuronal axis (18). This glucose lowering effect of duodenal lipids is dependent on intracellular esterification of long-chain fatty acids (LCFAs) to long-chain fatty acyl-CoA (LCFA-CoA) via acyl-CoA synthetase (ACS)-3 (Figure 2), indicating the importance of both luminal lipid hydrolysis to LCFAs and subsequent absorption into intestinal cells possibly via fatty acid transporter cluster determinant 36 (CD36) (19). Although the role of CD36 in mediating the glucoregulatory role of lipids remains to be tested, it is interesting to note that CD36 knockout mice exhibit reduced release of CCK both in vivo and in vitro (19). Furthermore, LCFA-induced secretion, and glucose-lowering effect of CCK is dependent upon protein kinase C-δ (PKC-δ) stimulation, which is localized to the duodenal mucosal layer (20, 21). However, the mechanistic link between PKC-δ signaling and CCK secretion remains to be investigated. Nevertheless, this LCFA->PKC-δ->CCK pathway requires activation of CCK-1 receptors (CCK-1R), located on the vagal afferent fibers innervating the small intestine (22). Binding of CCK to its receptor leads to protein kinase A (PKA) signaling, which is sufficient and necessary to enhance N-Methyl-D-aspartate (NMDA) receptor mediated neuronal transmission in the nucleus of the solitary tract (NTS) to lower GP via the hepatic vagal branch (Figure 2) (23). Taken together, these results suggest that paracrine CCK action mediates the ability of duodenal lipids to regulate glucose homeostasis by signaling to the central nervous system.

Interestingly, this ability of CCK and intestinal lipids to reduce GP is diminished when rats are placed on a three-day high-fat (HF) diet (18, 24), that much resembles the western diet, highlighting the pathophysiological relevance of this pathway. Closer analysis indicates this diet induces CCK resistance at the level of the CCK-1R signaling by impairing PKA activation and subsequently, the gut-brain-liver axis (23). Thus, the ability to manipulate gut CCK signaling may prove an efficacious therapeutic option, evidenced by the fact that improvements in glycemic control were seen in humans with impaired glucose tolerance after 8 week treatment of the bile acid sequestrant, colesevelam. These improvements were as a result of colesevelam preventing bile acid absorption and thus increasing local CCK secretion, which possibly activates the aforementioned glucoregulatory pathway (25).

**GLP-1 Action in the Gut**

While CCK signaling appears to mediate the glucose lowering effects of intestinal lipids, GLP-1, which is released predominately from L-cells of the distal intestine (Figure 1), has been extensively studied for its incretin effect. GLP-1 secretion is biphasic, with the early peak (within minutes) attributed to a neurohormonal reflex (26) although recent studies argue for direct nutrient exposure of proximal L-cells (27, 28) and the later peak mediated by direct nutrient stimulation of distal intestinal L-cells (29). Interestingly, both glucose and fatty acids are potent stimulators of GLP-1 release; however the receptors and intracellular mechanisms mediating GLP-1 secretion are contentious and remain to be clarified (see (30)). The glucoregulatory action of
GLP-1 has been widely established since the pioneering study demonstrated its potent incretin effect almost 3 decades ago (31). Indeed, GLP-1 acts on the GLP-1R localized on the outer membrane of pancreatic β-cells to promote insulin secretion via activation of PKA-dependent and independent pathways. Additionally, GLP-1 action in the pancreas inhibits glucagon and stimulates somatostatin release, and also increases β-cell sensitivity to glucose, insulin biosynthesis, and proliferation (32). However, GLP-1 is rapidly degraded by DPP-4, resulting in a diminished concentration of GLP-1 in the hepatoportal vein (~50%), and an even smaller amount entering systemic circulation (less than 10%) (33). As such, studies have hypothesized that insulin release, as well as other glucoregulatory effects like glucose utilization, GP, and counterregulatory hormone production, are all mediated by a gut-brain-periphery axis (34), involving the enteric nervous system, especially in the hepatic portal region (35). Indeed, findings have demonstrated that glucose-induced GLP-1 secretion activate vagal afferent neurons of the common hepatic branch activating the NTS (34, 36, 37). This signal is then relayed to the hypothalamus, which generate efferent signals to control glucose flux (36). Studies demonstrate that both the sensory and motor components of the vagus are essential, because blockade of the afferent or efferent vagal relay attenuates the increase to GLP-1R mediated insulin release (38). However, this GLP-1 dependent enteric glucose sensor is not entirely straightforward, as GLP-1 alters glucose utilization only when the hepatoporal glucose gradient conditions mimic the postprandial state (39). Furthermore, selective surgical removal of the common hepatic branch of the vagus did not abolish the glycemic effects of endogenous GLP-1, indicating that vagal afferents innervating the intestinal tract may be more important in mediating GLP-1-induced incretin signaling (40).

Postprandial levels of active GLP-1 are diminished in obese and diabetic individuals (41) leading to the development of GLP-1R agonists (exenatide and liraglutide) and DPP-4 inhibitors as type 2 diabetic treatments (42), which are moderately successful in improving glycemic control. Interestingly, success of these GLP-1 modifying treatments has been attributed to upregulation of this local GLP-1 gut-brain-periphery axis. For example, oral administration of low doses of DPP-4 inhibitor, sitagliptin, aimed at selectively inhibiting intestinal, but not systemic DPP-4 activity, still resulted in enhanced glycemic control and plasma insulin levels through activation of local GLP-1R on the vagus nerve. This indicates a predominant role for enhancement of the GLP-1 gut-brain-periphery axis in the ability of sitagliptin to reduce local intestinal DPP4 activity and regulate glycemia (43). Furthermore, the rapid remission of T2D following gastric bypass surgeries has been hypothesized to be mediated by GLP-1 (44, 45). Indeed, gastric bypass results in dramatically and rapidly enhanced meal-stimulated GLP-1, independent of weight loss and calorie restriction, likely from more direct nutrient exposure to intestinal L-cells (45). Furthermore, antagonism of the GLP-1R following Roux-en-Y gastric bypass (RYGB) worsens glucose tolerance and postprandial insulin secretion (46). Additionally, responsiveness to GLP-1R agonism in rodents was able to predict improvements in glycemic control following bariatric surgery, independent of weight loss (47). Despite this, both vertical sleeve gastrectomy and RYGB are effective in normalizing glycemia in several models of models of GLP-1 receptor deficiency (48, 49), while DJB improves glucose levels despite non-elevated post-surgical GLP-1 levels in nonobese type 1 diabetic rats (50). Thus, the role of GLP-1 in mediating the anti-diabetic effects of bariatric surgery still remains highly controversial (44, 45, 51–55).

**Jejunal Nutrient Sensing**

Although bariatric surgery is primarily used as a weight loss procedure for morbidly obese subjects, patients with type 2 diabetes very often exhibit rapid remission of diabetes. This led to the emergence of “metabolic surgery” as a new area of research and treatment (56). Indeed, studies in both rodents and humans demonstrate the glucose lowering effects of RYGB surgery and sleeve gastrectomy (57, 58), the more common surgical procedures used today. Although these surgical techniques include a restrictive component (reduction of stomach size), the improvement in glucose levels are not correlated with changes in body weight (46, 59–
In order to determine the effects of gastric restriction versus the involvement of the small intestine itself to regulate glucose control, an experimental surgical procedure was developed: duodenal-jejunal bypass surgery (DJB). This surgical technique leaves the stomach intact but bypasses the proximal intestine, increasing the flow of nutrients directly into the jejunum and producing rapid anti-diabetic effects. In Goto Kakizaki rats, a rodent model of non-obese type 2 diabetes, DJB improved glycemic control in as little as one week postoperatively, with no changes in body weight (62). Rapid weight-independent improvements in glycemia are also consistent with DJB in non-obese or mild obese type 2 diabetic humans (63–66). These studies suggest that the rearrangement of the intestinal tract mediates the glucose lowering effects of DJB. In light of the possibility that gut hormonal signaling contributes to the clinical and therapeutic anti-diabetic outcomes of bariatric surgery as discussed above, this suggests that nutrient sensing, which mediates gut hormonal release, may play a role in bariatric surgery’s effect.

Nutrient sensing in the distal portions of the small intestine, from an increased flux of unabsorbed nutrients, could play a role in the anti-diabetic effects of DJB. In rats, administration of both glucose and lipids into the jejunum decreases GP through a gut-brain-liver axis, likely via nutrient uptake and metabolism in intestinal cells and subsequent neuronal signaling (Figure 2) (50). To determine the importance of nutrient sensing in DJB, this bariatric surgical technique was performed in two strains of insulin-deficient uncontrolled diabetic rodents, the diabetes prone Biobreeding (BBdp) and non-obese uncontrolled streptozotocin (STZ)-induced rats. Interestingly, DJB resulted in a rapid reduction in plasma glucose levels (two days post-operative) independent of weight loss (50). While a physiological shunting of nutrients into the distal intestine achieved by refeeding activated jejunal nutrient sensing to maintain plasma glucose concentrations, blocking jejunal nutrient sensing reversed the beneficial glucose-lowering effects of DJB. Importantly, the rapid 2-day glucose lowering effect of DJB is independent of insulin action in both models (50).

Traditionally, insulin action has been thought to be an important mediator of glucose homeostasis through its actions on the liver, muscle, adipose tissue, and more recently, the brain. However, studies indicate that the hormone leptin can lower blood glucose concentrations in uncontrolled STZ-induced diabetic rodents independent of insulin action, described later, suggesting that insulin action may not be the sole mediator of glucose homeostasis. Contributing to this hypothesis, nutrient sensing mechanisms also remain intact in this rodent model to lower glucose concentrations after DJB surgery independent of a rise in insulin levels (50). This is consistent with other studies demonstrating that DJB suppresses GP in type 2 diabetic rodents without improving insulin sensitivity (52). These findings suggest that although insulin mediates glucose suppression in some settings, other local intestinal signals are important contributors to the anti-diabetic effects of DJB (Figure 2).

Gastric Leptin

Gastric leptin release

As discussed above, nutrient sensing plays an important role in the anti-diabetic effects of DJB. Although increased nutrient exposure to the distal small intestine likely results in increased release of CCK and GLP1, it is unlikely these peptides play a role in the ability of DJB to lower GP, as activation of jejunal PKA, a signaling pathway that mediates both CCK and GLP-1 receptor activation (67), has no effect on GP (23). However, CCK and GLP-1 receptors also signal through PKA-independent pathways in peripheral tissues (68–70), but whether these pathways exist in the intestine remains to be elucidated. Often disregarded, nutrient ingestion also results in the release of gastric leptin (71, 72), but its function in the intestine beyond control of food intake (73) remains largely unknown.

Gastric-derived leptin is predominantly secreted from the stomach’s fundic region (71, 72) as well as in gastric epithelial cells (74). While studies mostly focus on adipocyte-derived leptin and its central actions to control feeding, nutrient ingestion has been demonstrated to cause the release of gastric leptin (71, 72) directly into the gastric lumen (74, 75). Importantly, in order for gastric leptin to reach the intestine, it must withstand the harsh proteolytic environment of the
stomach. It is postulated that leptin is secreted as a complex with the soluble leptin receptor (SLR), a peptide that resembles the extracellular domain of the leptin receptor (75). The SLR prevents leptin’s degradation, and allows it to enter the intestine to subsequently bind and activate the functional long form leptin receptor (Ob-Rb) (76). In contrast to these findings, a study in humans suggests that gastric leptin is not bound to macromolecules such as the SLR (77) and in vitro studies suggest that leptin is unable to bind and activate the Ob-Rb when complexed to the SLR (78, 79). While the effect of the SLR on leptin action remains unclear, leptin has been detected in duodenal juices and thus reaches the duodenum in its intact form (73). Furthermore, the Ob-Rb is found to be expressed on cells of, or vagal afferents innervating, the small intestine (76, 80–83), and activation of these receptors results in various functions, such as regulating nutrient transport (84). Notably, leptin administration in the intestinal lumen inhibits the recruitment of sodium-glucose transporters to the apical membrane, hindering intestinal glucose absorption, and demonstrating a role for leptin in regulating glucose control (85). Moreover, similar to i.c.v. leptin, jejunal nutrient sensing lowers GP and mediates the anti-diabetic effects of DJB surgery independent of insulin action. These data suggest a role for gastric leptin in mediating the anti-diabetic effects of DJB. Thus, we aimed to dissect leptin role in the intestine to regulate glucose homeostasis and its potential in mediating DJB surgery’s anti-diabetic effect.

Leptin signaling and action

The effects of leptin on glucose regulation have been extensively studied in the brain. Leptin binds to the hypothalamic Ob-Rb and activates downstream effectors STAT-3 via Jak-2 (86, 87) and PI3K through phosphorylation of IRS (88), to regulate glucose homeostasis. Importantly, subcutaneous leptin administration in insulin deficient diabetic rodents normalizes glucose levels (89–91). This effect is likely mediated by the CNS, as i.c.v. leptin lowers plasma glucose levels in insulin-deficient rodents (92, 93), emphasizing the insulin-independent ability of leptin to lower glucose levels. Interestingly, both STAT-3 (83, 84) and PI3K (94) are also present in the gut, and leptin has been shown to activate intestinal STAT-3 to protect against infection (95). Therefore, it is possible that leptin acts on STAT3 and/or PI3K in the intestine to affect glucose homeostasis, as it does in the CNS.

Jejunal leptin lowers GP via a neuronal mediated Ob-Rb → PI3K signaling cascade

An intestinal leptin infusion was administered to determine its pre-absorptive effects on glucose regulation. While duodenal leptin did not affect glucose homeostasis, jejunal leptin increased the glucose infusion rate needed to maintain euglycemia, which was due to a decrease in GP, rather than an increase in peripheral glucose uptake during the clamps (96). This effect was mediated by the Ob-Rb, as coinfusion of leptin with a chemical inhibitor or infusion of jejunal leptin in two leptin receptor deficient rodent models, the Koletsky fa+/fa+ rats and db/db mice, abolished the glucoregulatory effect of leptin. Furthermore, activation of PI3K, and not STAT3, was required for intrajejunal leptin to lower GP as infusion of the STAT3 inhibitor with leptin failed to negate its glucose lowering effects, but inhibiting PI3K abolished the ability of leptin to lower GP (96). It is interesting to note that duodenal leptin was unable to lower GP, and likewise failed to increase PI3K activity indicating that PI3K activation may mediate the glucose lowering effect of leptin. Given our previous work detailing a gut-brain-liver neuronal axis to lower GP (97, 98), we tested the involvement of a neuronal network in mediating the effects of leptin. The local anesthetic tetracaine was infused to block neuronal innervation of the jejunum, which consequently abolished the ability of leptin to increase the GIR and suppress GP (96). Thus, jejunal leptin triggers a neuronal-mediated Ob-Rb → PI3K signaling cascade to lower GP. Although untested, it is possible that similar to CCK acting on gut vagal afferents to lower GP, gastric leptin may activate Ob-Rb receptors on vagal afferents terminating in the jejunal lamina propria, as the Ob-Rb receptor has been detected in the nodose ganglia (81, 99).
Jejunal leptin lowers GP in diseased models

As hypothalamic leptin is demonstrated to lower GP in rats fed a HF diet for three days, jejunal leptin action was tested in this same model. Rats develop duodenal CCK-resistance after three days of hyperphagic HF-feeding, however jejunal leptin actions remained intact and it was able to lower GP in this rodent model. Moreover, leptin also lowered GP and plasma glucose levels in uncontrolled STZ induced-diabetic rats with insulin levels reduced by ~80%, independent of changes in plasma insulin (96). This indicates that while duodenal nutrient/CCK-resistance may demonstrate a possible pathophysiological role in the development of diabetes, the success of jejunal leptin in diseased states demonstrates a potential role for gastric leptin in mediating the glucose lowering effect of DJB.

Jejunal leptin mediates DJB’s anti-diabetic effects

Therefore, to test leptin’s involvement in mediating the anti-diabetic effects of DJB, we performed fasting-refeeding studies to stimulate physiological gastric leptin release in STZ-diabetic rats that had received DJB surgery, while disrupting leptin signaling. While glucose control remained intact in rats with a jejunal saline infusion, it was disrupted by blocking leptin signaling. However, blockade of leptin signaling did not disrupt glucose homeostasis to same extent as seen in STZ-diabetic rodents who had received SHAM surgery (96). Thus, other factors influencing glucose control could be at play, and it may be that nutrient sensing mechanisms and leptin signaling in the jejunum converge to control glucose homeostasis after DJB surgery (Figure 2).

Conclusion

In a recent review, Schwartz and colleagues elegantly proposed a ‘revised’ two-compartment model for the pathogenesis of type 2 diabetes (100). As opposed to the traditional islet malfunction-centered view, this model suggests that diabetes develops from a cooperative failure of glucose homeostasis from both pancreatic islets and a brain-centered glucoregulatory system. In light of accumulating research presented in this review, we argue that the gastrointestinal tract should also be recognized as a major player in this ‘revised’ model of type 2 diabetes pathogenesis. The importance of this ‘second brain’ in glucose homeostasis is often overlooked, despite its central location and highly intricate and bi-directional signaling pathways. Indeed, the gut represents the initial target site of nutrients, mediating the influx of glucose and other metabolic products. Furthermore, as highlighted in this review, the gut produces the initial meal-induced feedback signals to the rest of the body, via neuronal and hormonal signals. These gut-derived peptides, such as CCK and GLP-1, exhibit both insulin-dependent and –independent glucoregulatory mechanisms, indicating a link from the gut to both the brain and the pancreas. Rapid failure of this gut-brain axis in mediating glucose homeostasis in diseased conditions (18, 23, 24) may both precede and contribute to the initial dysregulations of the brain and islets.

Thus, we propose that the gut lies upstream of this two-compartment model, where early impairments in gut function may be the initial stimulus that leads to initial damages of both the brain and islet glucoregulatory systems, that subsequently worsen into the development of diabetes. The best support of this hypothesis comes from the fact that the most effective treatment of type 2 diabetes to date is from remodeling of the gut via bariatric surgery. Although the underlying mechanism(s) resulting in rapid normalization of glucose homeostasis after bariatric surgery is still unknown, it likely involves gut-initiated restoration of both insulin-dependent and neuronal-mediated insulin-independent mechanisms. Indeed, evidence suggests that early changes in incretin levels may contribute to the rapid remission of types 2 diabetes, while we have demonstrated the importance of insulin-independent nutrient and hormonal gut-brain-liver signaling axis in restoring glucose homeostasis. Therefore, the ability to manipulate this ‘second brain’ may be an effective strategy to target both the islet-centered and brain-centered glucose control systems, and improve the management of type 2 diabetes.

Acknowledgments

The work discussed in this review is supported by a research grant to T.K.T.L. from the Canadian
Institutes of Health Research (CIHR-MOP-82701). C.D.C. is supported by a Banting and Best Diabetes Centre graduate studentship. B.A.R. is supported by a CIHR Doctoral Vanier Canada scholarship. F.A.D. is supported by a Toronto General Research Institute post-doctoral fellowship. T.K.T.L. holds the John Kitson McIvor (1915–1942) Endowed Chair in Diabetes Research and the Canada Research Chair in Obesity at the Toronto General Research Institute and the University of Toronto. No potential conflicts of interest relevant to this article were reported. C.D.C., M.Z.T, B.A.R, F.A.D. and T.K.T.L. developed the concept and wrote the manuscript. The authors apologize to colleagues whose work is not referenced.

References


FIGURE 1

Gut peptide hormones and regulatory signals are released along the length of the gastrointestinal tract. Both ghrelin and leptin are secreted from the stomach, while CCK, GIP are secreted from I cells and K cells, respectively, in the duodenum. It is debated whether L cells, which secrete GLP-1, GLP-2, OXN, and PYY, are located in the duodenum. More distally secreted in the intestine are CCK and GIP from the jejunum, and GLP-1, GLP-2, OXN, and PYY from the ileum.

FIGURE 2

Gut nutrient sensing mechanisms and subsequent peptide hormone release in normal and DJB surgery settings. Nutrient influx in both the duodenum and jejunum triggers hormonal release and downstream signaling to lower GP through a neuronal network. In the duodenum, these mechanisms are disrupted upon high fat feeding. DJB surgery results in the influx of nutrients and hormones, such as leptin, directly into the jejunum to suppress GP through downstream mechanisms.
FIGURE 1

Stomach

Ghrelin

Leptin

Small Intestine

Duodenum
- CCK
- GIP
- GLP-1, GLP-2?
- OXN, PYY?

Jejunum
- CCK
- GIP

Ileum
- GLP-1
- GLP-2
- OXN
- PYY
GLUCOSE PRODUCTION

jejunal lipid metabolism

Duodenum

Lipid $\rightarrow$ LCFA-CoA $\rightarrow$ PKC-δ $\rightarrow$ CCK $\rightarrow$ CCK-1 receptors $\rightarrow$ PKA

nts NMDA receptors

High Fat Feeding

 jejunal glucose metabolism

NUTRIENTS $\rightarrow$ LEPTIN $\rightarrow$ ACS

Lipid $\rightarrow$ LCFA-CoA $\rightarrow$ ?

? $\rightarrow$ Glucose $\rightarrow$ SGLT1 $\rightarrow$ ?

? $\rightarrow$ Leptin $\rightarrow$ Ob-Rb $\rightarrow$ PI3K $\rightarrow$ ?

FIGURE 2
Hormonal signaling in the gut
Clemence D. Cote, Melika Zadeh-Tahmasebi, Brittany A. Rasmussen, Frank A. Duca and Tony K. T. Lam

J. Biol. Chem. published online February 27, 2014

Access the most updated version of this article at doi: 10.1074/jbc.O114.556068

Alerts:
  • When this article is cited
  • When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2014/02/27/jbc.O114.556068.full.html#ref-list-1